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istening to the Endothelium
Story of Signal and Noise*
obert Vogel, MD, FACC
altimore, Maryland
ensing myriad physical and chemical stimuli, the endothe-
ium releases numerous messenger molecules that regulate
ocal vasoactivity, inflammation, mitogenesis, and thrombo-
is (1,2). Nitric oxide (NO) is an important local vasodilat-
ng messenger. Blood flow shear releases NO, which un-
erlies the phenomenon of flow-mediated dilation (FMD).
esides vasoregulation, NO has antiatherogenic effects, includ-
ng inhibition of white cell activation and smooth muscle cell
roliferation. The 1998 Nobel Prize for Medicine awarded to
obert Furchgott, Lewis Ignarro, and Ferid Murad acknowl-
dged the significance of endothelial function.
See pages 1953 and 1959
The standard for assessing endothelial function remains
easuring arterial diameter responses to endothelium-
ediated agonists, such as acetylcholine. Such an approach,
owever, disregards endothelium’s non–NO-mediated ef-
ects on inflammation and thrombosis (3). The evaluation of
oronary artery endothelium-mediated vasomotion is an
xacting, lengthy, invasive process, rarely performed for
linical reasons. An easily performed measure of endothelial
unction would, therefore, potentially serve as a useful
iomarker of developing atherosclerosis, a means for under-
tanding risk factors, and a monitor for antiatherogenic
nterventions.
In 1992, Celermajer et al. (4) demonstrated a novel,
oninvasive FMD-based approach to measuring endothelial
unction that assesses brachial arterial dilation by ultrasound
n response to the hyperemia produced by transient blood
ressure cuff arterial occlusion. Numerous laboratories have
xperimented with this technique, including ours. Assess-
ent of FMD has been both a rewarding and disappointing
xperience. Brachial artery FMD appears to be an integra-
ive index of risk factor burden. Using the FMD technique,
he relationship between established risk factors such as
ypercholesterolemia and endothelial function has also been
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or theh
merican College of Cardiology.
From the University of Maryland Hospital, Baltimore, Maryland.reatly clarified (5). Investigations have also demonstrated
hat several common activities such as eating, exercising,
motional distress, and sleep deprivation affect endothelial
unction (6,7).
Despite the many insights into vascular biology pro-
ided by this noninvasive approach, FMD has not proven
o be clinically useful, especially for predicting cardiovas-
ular risk. It is a biologically noisy index predominately
ecause it is influenced by countless clinical factors. It is
f greatest predictive value in low-risk individuals, but it
dds little to risk assessment beyond that provided by
tandard factors (8,9).
Beyond its intrinsic biological variability, brachial artery
MD measurements are technical difficult. Although con-
eptually simple, the accurate and reproducible measure-
ent of FMD (normal values exceed 6% to 8%) requires
killed sonographers performing large numbers of proce-
ures using high-frequency vascular probes with patience
nd care. With an average brachial artery diameter of 3 to 5
m, each 1% increment equates to 0.03 to 0.05 mm arterial
ilation measured over minutes.
In 2002, a group of experienced investigators summarized
he existing standards for the performance and measure-
ent of FMD (10). A lack of technical and interpretational
tandardization was evident in this summary. In this issue of
he Journal, Donald et al. (11) in Deanfield’s laboratory
ompare technical approaches to measuring FMD using
hort- and long-term reproducibility and discrimination of
ormal from diabetic and hypercholesterolemic subject val-
es as the end points. This long overdue report advances the
cience of this technique by reducing the inherent “noise.”
hey find that FMD is most reproducible and discriminat-
ng using a stereotactically held probe, continuous B-mode
vs. A-mode) ultrasonic imaging, automated edge detection
nd diameter measurement, and a maximum arterial diam-
ter end point (vs. fixed 60-s measurement). These technical
tandards should be adopted by other laboratories.
This report also provides power curves that estimate
ohort size required to measure specified FMD changes in
rossover and parallel design studies. Their estimates un-
erscore the difficulty in measuring small changes (1% to
%) in FMD using a parallel design, often required for
ongitudinal intervention and drug studies. Multicenter
tudies would almost certainly be required for the perfor-
ance of such trials since they estimate that 100 to 400
ubjects would be needed to detect an effect.
This report has 2 important limitations. This laboratory
as the most extensive experience in performing FMD
easurements, calling in question whether less experienced
aboratories might achieve the same 7% to 10% coefficient of
ariation reproducibility even using the same validated
pproach. Secondly, although their suggestions may reduce
he noise, they do not increase the “signal.” The reported
ifference in FMD between their normal and diabetic and
ypercholesterolemic subjects was only 2% to 3% (absolute).
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Editorial Comment May 20, 2008:1965–6n part, this small signal is due to the use of lower (as
pposed to upper) arm arterial occlusion, which has been
idely adopted because it is almost entirely NO dependent.
In a separate study in this issue of the Journal, Gori et al.
12) describe the inverse of FMD, namely brachial artery
ow-mediated constriction (FMC), measured during distal
rterial occlusion. They report that FMC is reduced in
ubjects who smoke or who have hypertension or coronary
rtery disease. The reduction in FMC in their smoking and
ypertensive subjects was similar to their reduction in
MD, but the reduction in FMC in coronary artery disease
ubjects was proportionally greater (i.e., a greater signal). By
umming individual FMC and FMD values, they report a
% to 9% absolute difference between their normal and
bnormal subjects compared with a 2% to 3% absolute
ifference in FMD as reported by Donald et al. (11). The
ncreased signal of summed FMC and FMD with the
educed noise inherent in the described technical advances
ay increase brachial imaging’s efficacy for clinical purposes
uch as predicting cardiovascular risk.
Importantly, FMC but not FMD was reduced by flucon-
zole, an inhibitor of endothelium-derived hyperpolarizing
actor and aspirin, an inhibitor of cyclooxygenase. Inhibiting
O synthase reduced FMD, but not FMC. Thus, the FMC
signal” is dependent on a non-NO, but endothelium-
ediated, process. Underscoring their different physiolo-
ies, FMC and FMD did not significantly correlate in this
tudy. To some purists, not measuring NO availability is a
isadvantage in the assessment of endothelial function. It
ay, however, be an advantage. It may be telling us a
ifferent, but equally interesting, story about other endothe-
ial messenger molecules. This initial report, however,
nvolves few subjects and at  least 3 messengers,
ndothelium-derived hyperpolarizing factor, prostaglan-
ins, and endothelin-1. It remains to be shown how clearly
nd loudly it will speak to us.
What is clear, however, is that medical science often
adly falters when we exclusively focus on single mecha-
isms in complex diseases. For example, we might predict
hat hormone replacement therapy would reduce cardiovas-
ular risk after learning that it improves endothelium-
ediated dilation. At the same time, hormone replacementherapy increases proatherogenic factors, such as inflamma-ion and coagulation, which are also endothelium mediated.
f these FMC observations are confirmed, one might view
MD and FMC as a panel of associated tests, much like
ow-density lipoprotein and high-density lipoprotein cho-
esterol, each telling an associated but different tale. Now
hat we have a better understanding of how to reduce the
oise, we should listen carefully to the full story the
ndothelium is trying to tell us.
eprint requests and correspondence: Dr. Robert A. Vogel,
niversity of Maryland Hospital, 22 South Greene Street,
oom S3B06, Baltimore, Maryland 21201. E-mail: rvogel@
edicine.umaryland.edu.
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